Acalabrutinib
A targeted oral therapy that inhibits an enzyme called BTK, which certain cancer cells and overactive immune cells depend on to grow and survive. It is used to treat certain blood cancers, including chronic lymphocytic leukemia and mantle cell lymphoma. Patients may experience headaches, particularly early in treatment, as well as an increased risk of bleeding and atrial fibrillation.
Moleküler Ağırlık
465,5000 g/mol
LogP
3,00
TPSA
119,00 Ų
Lipinski RO5
Geçer
Terapötik Alanlar
Etki Mekanizması
Irreversibly inhibits Bruton's tyrosine kinase (BTK), a key enzyme in the B-cell receptor signaling pathway that drives the survival and proliferation of malignant B cells.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Irreversibly inhibits Bruton's tyrosine kinase (BTK), a key enzyme in the B-cell receptor signaling pathway that drives the survival and proliferation of malignant B cells.
2D Yapı
Cite this structure
Embed this structure
SMILES
CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12
InChI
InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1
Molecular Formula
C26H23N7O2
HBD / HBA
2 / 6
Döndürülebilir Bağlar
4
Ağır Atomlar
35
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
A targeted oral therapy that inhibits an enzyme called BTK, which certain cancer cells and overactive immune cells depend on to grow and survive. It is used to treat certain blood cancers, including chronic lymphocytic leukemia and mantle cell lymphoma. Patients may experience headaches, particularly early in treatment, as well as an increased risk of bleeding and atrial fibrillation.
Irreversibly inhibits Bruton's tyrosine kinase (BTK), a key enzyme in the B-cell receptor signaling pathway that drives the survival and proliferation of malignant B cells.
Yes, Acalabrutinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3707348. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 71226662. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="acalabrutinib"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/acalabrutinib/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/acalabrutinib/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/acalabrutinib/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="acalabrutinib"></drugfyi-drug>